ASCO 2026: Bayer Shares New Findings for NUBEQA® (Darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Key Takeaways

• Darolutamide reduced cognitive decline by 20% versus enzalutamide.
• Median MCCD change: -15.8% for darolutamide, -36.1% for enzalutamide.
• 23 patients switched from enzalutamide to darolutamide after cognitive decline.
• Phase II ARACOG trial enrolled 111 men with advanced prostate cancer.
• Bayer 2025 sales €45.6 billion (~$50 billion) and R&D €5.8 billion (~$6.4 billion).

Pulse Analysis

The ARACOG head‑to‑head Phase II trial, presented at ASCO 2026, provides the first robust evidence that darolutamide (NUBEQA) spares cognitive function in men battling metastatic or castration‑resistant prostate cancer. Using the CANTAB platform, researchers measured five cognitive domains and found a median 20‑percentage‑point advantage for darolutamide over enzalutamide. This neurocognitive benefit complements darolutamide’s established efficacy in slowing disease progression and may shift prescribing patterns toward a more holistic view of patient well‑being.

Clinicians now have data to discuss not only survival but also daily functioning when choosing an androgen‑receptor inhibitor. The trial’s open‑label design allowed 23 patients to cross over from enzalutamide to darolutamide after measurable decline, underscoring real‑world relevance. While the crossover criteria introduce some bias, the magnitude of the cognitive difference and the consistency across executive function and working memory domains suggest a genuine drug effect. Patient‑reported outcomes and longer‑term follow‑up will be critical to confirm durability of the benefit.

From a market perspective, the cognitive safety signal strengthens Bayer’s oncology franchise, which posted 2025 sales of €45.6 billion (≈$50 billion) and invested €5.8 billion (≈$6.4 billion) in R&D. As payers and providers increasingly value quality‑of‑life metrics, darolutamide’s differentiated profile could drive higher uptake and justify premium pricing. The results also signal to competitors that neurocognitive endpoints are becoming a differentiator in the androgen‑receptor inhibitor space, likely prompting more trials that integrate cognitive testing alongside traditional oncologic endpoints.